Articles On Neurotech International (ASX:NTI)

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has reached a critical milestone with the dosing of the initial patient using its unique treatment for Rett Syndrome. The first patient has now been enr...

The ASX 200 had a positive finish to the day on the whole, on the back of the rates pause from the RBA Sectors were a green scene, with IT and Staples leading the way Standout small caps: Viridis, Imricor and Baby Bunting, among several ot...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on progress of its lead candidate cannabinoid-based drug...

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has updated the market on progress of its lead candidate cannabinoid-based drug NTI164 to treat several paediatric neurological disorders where there is...

Neurotech is following in the footsteps of 2023 market darling of the ASX biotech sector Neuren with another possible treatment for Rett Syndrome. Biopharmaceutical company Neurotech International (ASX:NTI) has hopes of becoming the world’...

Social media platforms are rushing to update their advertising policies on cannabis Meta was the most recent platform to do so Australia’s TGA is clamping down on CBD advertising in Australia   With regulations on cannabis use moving fast...

With the Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) scheme clearance by the Therapeutic Goods Administration (TGA) under its wing, Neurotech will investigate the use of NTI164 in female Rett Syndro...

This content is created by Smallcaps Authors. [Author : Colin Hay] Specialist biopharmaceutical development company Neurotech International (ASX: NTI) has obtained critical approval to undergo testing of a potential treatment for Rett Syn...

Bod Science provided a ‘landmark update’ on its Phase IIB insomnia clinical trial Neurotech received an ethics approval to begin Phase I/II clinical trial Incannex intends to list all its shares on the Nasdaq   Bod Science provides ‘landm...

Zelira announced that its diabetic nerve pain drug outperforms Pfizer’s Lyrica Diabetes is a huge market, estimated at a massive US$62 billion in 2022 Stockhead reached out to Zelira’s CEO, Dr. Oludare Odumosu   Diabetes is one of the lea...

The weed industry has slumped as it faces several headwinds But new data suggests the industry will grow significantly over the next decade We take a look at how the ASX weed stocks have performed over the past week   As we head into the...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] The Human Research Ethics Committee (HREC) has granted Neurotech International (ASX: NTI) a two-year dosage extension for the use of lead drug NTI164 on autism spectru...

Neurotech will extend its Phase 1/2 trial after ethics approval Alcidion makes further inroads into UK’s public hospitals   Neurotech to extend Phase 1/2 trial after ethics approval Paediatric neurological disorders specialist, Neurotech...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has received Human Research Ethics Committee (HREC) approval to extend a curren...

Studies confirm that cannabis relieves pain in cancer patients In addition, cannabis also improves sleep and cognitive function in cancer patients We take a look at the biggest movers in ASX weed stocks over the past week   It’s now offic...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Neurotech International (ASX: NTI) has completed recruitment for a phase I/II trial assessing its lead candidate NTI164 in children with paediatric autoimmune neurops...

This content is created by Smallcaps Authors. [Author : Lorna Nicholas] Clinical stage biopharmaceutical company Neurotech International’s (ASX: NTI) plans for its phase II trial evaluating its NTI164 candidate in children with Rett syndr...

Chemist Warehouse joins WNX JV to develop new cannabis products Neurotech launches new clinical program for its NTI164 drug in Rett Syndrome InhaleRx nabs approval for Phase 1 IRX211 clinical trial for Complex Regional Pain Syndrome   Wel...

Healius gets takeover offer from ALC, a company more than half its size Neurotech will launch Phase 2 clinical trial in Rett Syndrome Germany allows Invex to commence the IIH EVOLVE Phase 3 clinical trial   Healius gets takeover offer fro...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has launched a new clinical program into the use of daily oral cannabinoid-base...

This content is created by Smallcaps Authors. [Author : Filip Karinja] Emerging drug developer Neurotech International (ASX: NTI) has reported further positive results from first-in-human clinical trialling of its lead drug candidate NTI-...

Neurotech (ASX:NTI) has today announced the final clinical results from its 11 paediatric Autism Spectrum Disorder (ASD) patients, following daily treatment of NTI164 over a 52-week period. The results showed strong safety and efficacy effe...

The ASX bounced back from the week’s drama to close up by 0.86% The XEC Emerging Companies Index closed 1.26% higher because it’s young and needed the money Former PM Paul Keating kicks a glorious own goal at the Australian Press Club   H...

This content is created by Smallcaps Authors. [Author : Filip Karinja] Emerging drug developer Neurotech International (ASX: NTI) is on a war against PANDAS – nothing to do with attacking China’s loveable piebald national symbol, but diff...

Twitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on top with CannaCare Health arbitration awarded in their favour Avecho expands CBD soft-gel capsule trials with the Lambert Initiative   Twi...

Neurotech International (NTI) treats its first patient in its phase one and two paediatric clinical trials The trials are assessing the company’s NTI164 product in children with paediatric autoimmune neuropsychiatric disorders associated...

Neurotech International (NTI) is granted approval to begin phase one and two paediatric clinical trials The company received written approval from the Human Research Ethics Committee (HREC), along with clinical trial notification scheme...

US States who allow recreational cannabis see less codeine demand WA GP wants Snoop Dogg to drop into parliament to chat cannabis reform Neurotech nabs pre-submission meeting with US FDA for CBD drug NTI164   A Cornell University study ha...

Good gravy, what a Monday that was – the Stockhead newsroom’s been busier than Santa’s elves this week, as the ASX is inundated with last-minute, pre-Christmas stock market shenanigans. Maybe staying up to watch the World Cup final wasn’t s...

UBI will have its work published on the front cover of respected publication Neurotech gets green light for Phase II/III trial Sonic Healthcare’s revenue disappoints UBI’s work gets published Universal Biosensors (ASX:UBI) rose 6% this mo...

Neurotech International (NTI) taps investors for $9 million to fund its paediatric clinical trials programInstitutional, professional and sophisticated investors have made binding commitments for a placement comprising 90 million new shares...

Germany looks to legalise recreational cannabis and US and Canadian companies are paying attention  Neurotech reports success with its cannabis-based drug for paediatric autism symptoms  ECS Botanics has sold its Tasmanian business and a...

Neurotech says its NTI164 drug for paediatric autism showed improvements in symptoms Arovella closing Perth R&D facility to focus on invariant Natural Killer T (iNKT) cell platform Argenica reports safety and efficiacy of stroke drug A...

ASX200 is in the green on Wednesday morning New British PM brings yields back to Pre-Liz levels Amazon and Meta to report after the close tonight Local shares are set to open higher again on Wednesday morning after a rather light night of...

Tuesday. The day when the grind of the week is well and truly entrenched, and the weekend is just a wistful speck in the distance, beckoning us forward, inch by dreadful inch, with promises of sleeping late, fishing adventures and absolutel...

The ASX 200 trims gains to end circa 0.3% higher Small caps drop 0.2%, but C29 Metals booms China markets still choppy after political appointments   The big show, if balancing books and picking pre-chosen soundbytes is your thing, begins...

Patrys crosses blood brain barrier in health animals Cynata receives Notice of Acceptance from IP Australia Telix announces collaboration with GE Healthcare Patrys (ASX:PAB) surged 15% this morning after announcing that its full-sized deo...

Neurotech is anticipating results from its extended world first study of a medicinal cannabis product in children which could be a game-changer in autism treatment. Clinical-stage biopharmaceutical company focused predominantly on pediatric...

Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index   It turns out that the lazy stoner stereotype is actually a myth,...

Neurotech International has made key appointments and changes to its board as it focuses on its developing and commercialising neurological solutions, including a cannabis breakthrough for paediatric autism. Biopharmaceutical Neurotech Int...

It’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodgements. The last day for companies to submit reports is the last business day of the first month after the prior quarter. If they don’t, they...

The recent trial results success could pave the way to test other neurological illnesses, as well as an FDA approval Neurotech International (ASX:NTI) has recently announced ground-breaking results with respect to the safety, tolerability,...

Neurotech International (NTI) reports 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with ASD Under the trial, 14 patients aged eight to 17 received varying doses of NTI16...

MGC Pharma to go Phase 2 on COVID-19 in South Africa Neurotech says cannabis strain works well in children with Autism Spectrum Disorder Nova Eye’s revenue impacted by China lockdowns MGC Pharma set to start Phase IIb trial in South Afric...

Neurotech has released promising results from a world first study of a medicinal cannabis product in children which could prove to be a game-changer in autism treatment. Neurotech International (ASX:NTI) has released promising results from...

The ASX 200 and XEC small cap indices rise Attention turns to Tuesday’s date with RBA destiny Celsius Resources is hot   The ASX 200 and the Emerging Markets (XEC) indices are both trading higher on Monday up about 1.2%, ahead of tomorrow...

A medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed  Neurotech International aims to change. Developing a r...

A Thai university says adding cannabis to chicken feed has positive results on meat and egg quality Aussie cannabis campaigner now a Member of the Order of Australia MGC Pharma’s CBD treatment proves effective against brain tumors   Chian...

Neurotech International (ASX:NTI) has reported positive preclinical research demonstrating that its NTI164 can improve diclofenac efficacy at low doses.

Neurotech International’s (NTI) preclinical research demonstrates its proprietary cannabis strain can improve Diclofenac efficacy at low doses When combined with Neurotech’s NTI164, Diclofenac showed a 93 per cent reduction in the expressi...